Skip to main content
Caplight Logo









Shanghai IxCell Biopharmaceutical Co., Ltd.

Shanghai IxCell Biopharmaceutical Co., Ltd.

Private
ShanghaiHealthcare & Life Scienceshttps://ixcellbio.com/

Last Round

Early Funding

Aug 26, 2025

Company Overview

Shanghai IxCell Biopharmaceutical Co., Ltd. is a biotechnology company that specializes in the development and industrial production of cell-based drugs, including mesenchymal stem cell, induced pluripotent stem cell, and immune cell therapies.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service

AI Layer

Application

Keywords

cell therapyCDMOcontract manufacturingiPSCinduced pluripotent stem cellmesenchymal stem cellMSCimmune cell therapyGMP manufacturingbiotech manufacturingCAR-Tprocess developmentcell bankingdrug discovery servicesorganoid platform

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Shanghai IxCell Biopharmaceutical Co., Ltd. Comparables

Compare Shanghai IxCell Biopharmaceutical Co., Ltd. with similar companies based on industry and business-model similarity.

Shanghai IxCell Biopharmaceutical Co., Ltd. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
uBriGene Biosciences
83%
Jiangsu Hillgene Biopharmaceutical Co., Ltd.
83%
OBiO Technology
81%

Shanghai IxCell Biopharmaceutical Co., Ltd. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Early FundingAug 26, 2025
Series BMar 12, 2025
Series B ExtensionDec 16, 2022
Series BSep 29, 2022
Early FundingMar 1, 2021
Series A
Nov 13, 2020

Shanghai IxCell Biopharmaceutical Co., Ltd. Investors

Notable investors and investment history

Shanghai IxCell Biopharmaceutical Co., Ltd. investors
InvestorRounds
Kailian CapitalEarly Funding, Series B
Shenzhen Dachen Caizhi Venture Capital ManagementSeries B
Guangdong Technology Financial GroupSeries B Extension
Tasly CapitalSeries A
SDIC Venture CapitalSeries B Extension
Zhejiang Huaou Venture CapitalEarly Funding, Series A
新丝路金控Series B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 26, 2025

    Raised capital from Kailian Capital and Zhejiang Huaou Venture Capital.

  • Mar 12, 2025

    Completed a Series B funding round.

Shanghai IxCell Biopharmaceutical Co., Ltd. Filings

Explore SEC and related filing metadata, where available.

Shanghai IxCell Biopharmaceutical Co., Ltd. filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Shanghai IxCell Biopharmaceutical Co., Ltd.'s valuation, stock price, and market status.

Is Shanghai IxCell Biopharmaceutical Co., Ltd. a public or private company?

Shanghai IxCell Biopharmaceutical Co., Ltd. is a private company.

What is the current stock price of Shanghai IxCell Biopharmaceutical Co., Ltd.?

Shanghai IxCell Biopharmaceutical Co., Ltd. is a private company with no public stock price. Caplight tracks Shanghai IxCell Biopharmaceutical Co., Ltd.'s secondary market activity and provides MarketPrice™ estimates to Caplight users.

How much is Shanghai IxCell Biopharmaceutical Co., Ltd. worth (valuation)?

Valuation information for Shanghai IxCell Biopharmaceutical Co., Ltd. is not publicly available.

Can I buy Shanghai IxCell Biopharmaceutical Co., Ltd. stock?

Shanghai IxCell Biopharmaceutical Co., Ltd. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Shanghai IxCell Biopharmaceutical Co., Ltd.'s last funding round?

Shanghai IxCell Biopharmaceutical Co., Ltd.'s most recent funding round was Early Funding on August 26, 2025.

Who are the main investors in Shanghai IxCell Biopharmaceutical Co., Ltd.?

Key investors in Shanghai IxCell Biopharmaceutical Co., Ltd. include Kailian Capital, Shenzhen Dachen Caizhi Venture Capital Management, Guangdong Technology Financial Group, Tasly Capital, SDIC Venture Capital.

Will Shanghai IxCell Biopharmaceutical Co., Ltd. IPO soon?

No public IPO plans have been announced for Shanghai IxCell Biopharmaceutical Co., Ltd..

How can I track Shanghai IxCell Biopharmaceutical Co., Ltd. secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Shanghai IxCell Biopharmaceutical Co., Ltd.'s secondary market activity and sign up for updates.

Firmographic Details

HeadquartersShanghai
Year Founded2013
Last FundingAug 26, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?